

**AMENDMENTS TO THE CLAIMS**

1. **(Withdrawn, Currently Amended)** A method for inducing a cytotoxic T cell (hereinafter, referred to as "CTL") comprising bringing peripheral lymphocyte cells into contact with a protein, wherein said protein comprises:

(i) the amino acid sequence shown in SEQ ID NO: 2; or

~~(ii) an amino acid sequence wherein one or more amino acids are deleted, substituted and/or added in the amino acid of SEQ ID NO: 2; or~~

~~(iii)~~ (ii) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2

wherein the amino acid residue at position 2 of said peptide is tyrosine, phenylalanine, methionine, or tryptophan, and/or the C terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine, and

~~wherein a cell expressing said protein is recognized by CTLs, or~~

~~—————(iv) wherein a partial peptide of said protein which is 8-14 amino acids long bindssaid peptide can bind~~ to an HLA antigen in an HLA-A24 or HLA-B55 restricted manner and is recognized by CTLs when bound to HLA-A24 or HLA-B55 antigen.

2. **(Currently Amended)** A peptide which is 8-14 amino acids long, and is:

(a) a partial peptide of a protein, wherein the protein consists of

(i) the amino acid sequence shown in SEQ ID NO: 2; or

~~(ii) an amino acid sequence wherein one or more amino acids are deleted, substituted and/or added in the amino acid sequence SEQ ID NO: 2; or~~

~~(iii)~~ (ii) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2;

wherein the amino acid residue at position 2 of said peptide is tyrosine, phenylalanine, methionine, or tryptophan, and/or the C terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine, and wherein a cell expressing said protein is recognized by CTLs; or

~~(b) a peptide comprising the amino acid sequence of (a) wherein the amino acid residue at position 2 is substituted by tyrosine, phenylalanine, methionine, or tryptophan, and/or the C terminal amino acid is substituted by phenylalanine, leucine, isoleucine, tryptophan, or methionine; and said peptide can bind to an HLA antigen in an HLA-A24 or HLA-B55 restricted manner and is recognized by CTLs when bound to an HLA-A24 or HLA-B55 antigen.~~

3. **(Cancelled)**

4. **(Previously Presented )** The peptide of claim 2, which comprises an amino acid sequence shown in any one of SEQ ID NO: 6 - 46.

5. **(Cancelled)**

6. **(Previously Presented)** An epitope peptide comprising a peptide of claim 2.

7. **(Previously Presented)** An inducer of CTL comprising a peptide of claim 2 as an active ingredient.

8.-11. **(Cancelled)**

12. **(Withdrawn, Currently amended)** A method for producing an antigen-presenting cell comprising the step of bringing a cell having antigen-presenting ability into contact with

(a) a protein comprising:

(i) the amino acid sequence shown in SEQ ID NO: 2; or

~~(ii) an amino acid sequence wherein one or more amino acids are deleted, substituted, and/or added in the amino acid sequence SEQ ID NO: 2; or~~

~~(iii)~~ (ii) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2

~~Wherein~~ wherein the amino acid residue at position 2 of said peptide is tyrosine, phenylalanine, methionine, or tryptophan, and/or the C terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine, and wherein said peptide can bind to an HLA antigen in an HLA-A24 or HLA-B55 restricted manner and is recognized by CTLs when bound to an HLA-A24 or HLA-B55 antigen. a cell expressing said protein is recognized by CTL; or

~~(b) a peptide set forth in claim 2~~

13. (Cancelled)

14. **(Withdrawn, Currently amended)** A method for inducing a CTL comprising the step of bringing peripheral lymphocyte cells into contact with

(a) a protein comprising

(i) the amino acid sequence shown in SEQ ID NO: 2; or

- ~~(ii) an amino acid sequence wherein one or more amino acids are deleted, substituted, and/or added in the amino acid sequence SEQ ID NO: 2; or~~
- (iii)(ii) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2

Wherein the amino acid residue at position 2 of said peptide is tyrosine, phenylalanine, methionine, or tryptophan, and/or the C terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine, and wherein said peptide can bind to an HLA antigen in an HLA-A24 or HLA-B55 restricted manner and is recognized by CTLs when bound to an HLA-A24 or HLA-B55 antigen-a cell expressing said protein is recognized by CTL; or

~~(b) a peptide set forth in claim 2.~~

15.-18. **(Cancelled)**

19. **(Currently Amended)** A tumor marker comprising a peptide as set forth in claim 2-.

20. **(Original)** The tumor marker of claim 19, which comprises at least 8 contiguous amino acids in the amino acid sequence shown in SEQ ID NO: 2.

21.- 24. **(Cancelled)**

25. **(Previously Presented)** The tumor marker of claim 19, wherein the tumor is sarcoma or renal cancer.

26. **(Previously Presented)** A diagnostic agent for tumor comprising a tumor marker of claim 19.

27. **(Cancelled)**